Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Ebastine
Cat. No.:
OB0225LY-0134
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Ebastine is a second-generation antihistamine that is selective and less likely to cause drowsiness.
Synonym:
Ebastel; LAS-W 090; Ebastin; Kestine; RP64305; 90729-43-4; 1-(4-tert-Butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; 4-(4-Benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one; 4-(4-(Benzhydryloxy)piperidin-1-yl)-1-(4-(tert-butyl)phenyl)butan-1-one
CAS No.:
90729-43-4
Compound CID:
3191
Formula:
C32H39NO2
Formula Weight:
469.66
Specification
Relative Density:
1.09 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Ebastine can be used to develop anti-allergy drugs such as allergic rhinitis and urticaria.
Library Information
Targets:
Histamine receptor family
Receptors:
H1 receptor
Pathways:
Neuronal signaling; Immunology/Inflammation; GPCR/G protein
Plate Number:
AOCL-2
Plate Location:
f7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
4.69 mg/mL; 10 mM
